These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

868 related items for PubMed ID: 25788382

  • 1. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB.
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [Abstract] [Full Text] [Related]

  • 2. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [Abstract] [Full Text] [Related]

  • 3. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR.
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [Abstract] [Full Text] [Related]

  • 4. Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
    Ackefors M, Castedal M, Dahlgard O, Verbaan H, Gjertsen H, Wernerson A, Weiland O.
    Infect Dis (Lond); 2015 Apr; 47(4):209-17. PubMed ID: 25650729
    [Abstract] [Full Text] [Related]

  • 5. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.
    Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, Tame MR, Piscaglia F, Andreone P, Bologna Liver Transplantation Group (BLTG), Ballardini G, Bernardi M, Bianchi FB, Biselli M, Bolondi L, Cescon M, Colecchia A, D'Errico A, Del Gaudio M, Ercolani G, Grazi GL, Grigioni W, Lorenzini S, Pinna AD, Ravaioli M, Roda E, Sama C, Vivarelli M.
    Aliment Pharmacol Ther; 2008 Aug 15; 28(4):450-7. PubMed ID: 18549463
    [Abstract] [Full Text] [Related]

  • 6. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
    Campos-Varela I, Castells L, Esteban JI, Bes M, Rodríguez-Frías F, Sapisochin G, Allende H, Charco R, Esteban R.
    Transplantation; 2012 Feb 27; 93(4):450-3. PubMed ID: 22262129
    [Abstract] [Full Text] [Related]

  • 7. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
    Pillai AA, Lee VS, Wang E, Rinella ME, Levitsky J.
    Transplant Proc; 2010 Nov 27; 42(9):3647-51. PubMed ID: 21094833
    [Abstract] [Full Text] [Related]

  • 8. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N, Sprinzl MF, Zimmermann T, Wörns MA, Zimmerer T, Galle PR, Stremmel W, Eisenbach C, Stein K, Antoni C, Schattenberg JM, Pathil A.
    BMC Gastroenterol; 2015 Aug 04; 15():97. PubMed ID: 26239732
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun 04; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 10. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.
    J Gastroenterol Hepatol; 2007 May 04; 22(5):669-75. PubMed ID: 17444854
    [Abstract] [Full Text] [Related]

  • 11. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J.
    J Hepatol; 2005 Jul 04; 43(1):53-9. PubMed ID: 15876467
    [Abstract] [Full Text] [Related]

  • 12. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodriguez M, Bernal C, Suarez F, Antela A, Olivares S, Del Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, Perez I, González-García J, Esteban-Mur JI, Miro JM, FIPSE LT-HIV Investigators.
    J Hepatol; 2015 Jan 04; 62(1):92-100. PubMed ID: 25127748
    [Abstract] [Full Text] [Related]

  • 13. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S, Gheorghe L, Hrehoret D, Becheanu G, Herlea V, Popescu I.
    J Gastrointestin Liver Dis; 2008 Jun 04; 17(2):165-72. PubMed ID: 18568137
    [Abstract] [Full Text] [Related]

  • 14. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E.
    World J Gastroenterol; 2014 Nov 28; 20(44):16726-33. PubMed ID: 25469044
    [Abstract] [Full Text] [Related]

  • 15. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.
    Giusto M, Rodriguez M, Navarro L, Rubin A, Aguilera V, San-Juan F, Ortiz C, López-Andujar R, Prieto M, Berenguer M.
    Liver Transpl; 2011 Nov 28; 17(11):1318-27. PubMed ID: 21761553
    [Abstract] [Full Text] [Related]

  • 16. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N, Giannelli G, Antonaci A, Antonaci S.
    J Viral Hepat; 2008 Apr 28; 15(4):300-4. PubMed ID: 18307592
    [Abstract] [Full Text] [Related]

  • 17. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
    Pillai AA, Wedd J, Norvell JP, Parekh S, Cheng N, Young N, Spivey JR, Ford R.
    Am J Gastroenterol; 2016 Feb 28; 111(2):250-60. PubMed ID: 26832650
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
    Abdel-Wahab M, Abdel-Khalek EE, El-Gilany AH, Yassen AM, Al-Shobari M, Shiha U, Ali M, Sadani M, Salah T, Sultan AM, Elghawalby AN, Elmorshedi M, Al-Refaey AK, Abdalla U.
    Arab J Gastroenterol; 2017 Sep 28; 18(3):151-155. PubMed ID: 28958486
    [Abstract] [Full Text] [Related]

  • 20. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
    Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK.
    Dig Dis Sci; 2011 Aug 28; 56(8):2449-55. PubMed ID: 21706207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.